[ET Net News Agency, 19 October 2021] Morgan Stanley lowered its target price for Ali
Health (00241) to HK$18 from HK$21 and maintained its "overweight" rating.
The research house said it cuts its 1HFY22 and full year FY22 revenue forecasts to
reflect moderating growth of Tmall traffic and non-drug sales per the trend observed. It
expects 2HFY22 growth to trend better than 1H with more promotional activities. (RC)